Virtual Library
Start Your Search
O. Chirita
Author of
-
+
P2.03b - Poster Session with Presenters Present (ID 465)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P2.03b-097 - Prognostic Factors for Overall Survival among Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) (ID 4582)
14:30 - 14:30 | Author(s): O. Chirita
- Abstract
Background:
The LENS (Leading the Evaluation of Non-squamous and Squamous NSCLC) retrospective medical chart review was undertaken to describe characteristics, treatment patterns and outcomes among patients receiving systemic treatment for advanced/metastatic NSCLC in Europe. This analysis reports on prognostic factors associated with overall survival (OS) from start of first line treatment (1L).
Methods:
Patients with NSCLC stage IIIb/IV diagnosis between July 2009 and August 2011 were sampled from oncology/pulmonology practices in France, Germany, Italy, and Spain. Patients were followed to their most recent visit (data collected October 2013 to April 2014). Data were extracted from medical charts. Prognostic factors associated with OS from start of 1L were examined through Cox proportional hazard estimation. Independent clinically relevant variables included age, gender, tumor histology, and TNM disease stage. Additionally, variables for presence of metastases, prior administration of mutation (EGFR, ALK, KRAS) tests, surgery, and health insurance type were included. A backwards selection process (model 1) was applied to select the variables from the latter group with a significance level of 0.1. The remaining variables were entered into a second model 2 with all clinically relevant variables regardless of their significance. The final model 3 included all clinically relevant variables plus the significant variables from model 2.
Results:Significant Prognostic Factors for OS from Start of 1L (p<.05) in Final Multivariable Model
The analysis included data from 736 1L patients from 168 sites in the four countries, who were followed for a mean of 1.7 years (range: 22 days – 4.6 years) until the most recent visit (28.9%) or death (71.1%).Variable (Reference) Level Hazard Ratio (95%CI) P-Value Age Category at first diagnosis (<65 ) >79 2.6 (1.9-3.7) <.0001 Country (Germany) Spain 1.6 (1.2-2.0) <.0001 TNM disease stage (IIIB) IV 1.6 (1.2-2.1) <.0001 ECOG Score (0) 1 2+ 1.5 (1.2-1.9) 2.8 (2.1-3.7) <.0001 <.0001 Smoking (Never) Current Former 2.3 (1.7-3.2) 1.6 (1.2-2.1) <.0001 .005 Malignant Pleural Effusion (No) Yes 1.3 (1.0-1.5) .037 Any Mutation Testing Conducted (No) Yes 0.74 (0.6-0.91) .004 EGFR+ Mutation Test (Negative, Not Tested, Inconclusive) Yes 0.75 (0.6-0.97) .027 Surgery (No) Yes 0.36 (0.2-0.6) <.0001
Conclusion:
This rich multi-country clinical dataset provides insight into real world patient clinical, demographic, and treatment characteristics prognostic for OS. The results indicate survival worsened for patients who were older, with higher ECOG scores, TNM stage IV, and smokers. Prior surgery and EGFR testing were associated with improved survival. OS was not associated with insurance plan type.
-
+
P3.02a - Poster Session with Presenters Present (ID 470)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02a-033 - The Humanistic Burden Associated with Caring for Advanced NSCLC Patients in Europe - A Real World Survey of Caregivers (ID 5665)
14:30 - 14:30 | Author(s): O. Chirita
- Abstract
Background:
While the financial aspects of the burden on caregivers for patients with advanced Non-Small Cell Lung Cancer (aNSCLC) have been estimated, limited published information exists on the humanistic burden incurred by these caregivers.
Methods:
Data were taken from a multi-center, cross-sectional study of aNSCLC patients and their caregivers conducted in France, Germany and Italy. The study consisted of three components: medical chart review, patient questionnaire and caregiver questionnaire. Overall, 683 consulting patients and 277 accompanying informal caregivers were recruited via treating physicians. The impact on health related quality of life was measured using the EuroQoL-5D (EQ-5D-3L) while caregiver burden was quantified using the Zarit Burden Interview (ZBI), which consists of 22 items, each rated 0-4. ZBI scores were grouped into: little/no burden (0-20), mild/moderate (21-40), moderate/severe (41-60) and severe burden (61-88). Scores of 24+ were assumed to identify caregivers at risk of depression. Analysis, conducted on 277 matched patient and caregiver forms, was stratified by country and by patients’ line of therapy. Statistical significance was assessed using Mann-Whitney U tests.
Results:
Caregivers’ mean (SD) age was 55.2 (13.0) years; 78.6% were female and 62.3% were the patient’s partner/spouse. Patients’ mean (SD) age was 66.2 (9.7); 73.6% were male and 91.0% had Stage IV NSCLC. Over two-thirds (70.4%) of patients were receiving 1[st] line advanced therapy, while 29.6% were receiving later lines of therapy. The mean (SD) EQ-5D-3L index for caregivers was 0.87 (0.19). Differences in EQ-5D-3L were observed between carers of 1[st] line patients and later line patients (0.89 v 0.83 p=0.003). The mean ZBI score for caregivers was 32.1 (15.6); A quarter (24.0%) of caregivers had little/no burden, 44.6% mild/moderate, 28.8% moderate/severe and 2.6% severe burden; 69.7% of caregivers were identified as at risk of depression. Differences in ZBI were observed between carers of 1[st] line patients and later line patients (30.9 v 34.9 p=0.099).
Conclusion:
Comparing these results with other published ZBI data, the burden suffered by aNSCLC patient caregivers appears to be higher than other conditions studied in Europe, namely , Parkinson’s disease (25.8) another study conducted across advanced cancer (18.5). Caregivers for aNSCLC patients suffer significant humanistic burden in addition to the overall burden faced by patients and is likely to result in additional costs. When assessing the impact of a treatment, the potential to improve the impact on caregivers should also be included.
